Objectives: We aimed to analyze the clinical features of Miller Fisher syndrome (MFS) in southern China and compare it features presenting in other countries. Methods: Medical records of patients with a diagnosis of Guillain-Barré syndrome (GBS) admitted to 31 tertiary hospitals, located in 13 provinces in southern China, from 1 January 2013 to 30 September 2016, were collected and retrospectively reviewed. Results: A total of 72 patients (36 from rural area and 36 from urban area) were enrolled. Their age at onset was 47.42±15.65 years old. Winter (29.2%) and spring (41.7%) were the seasons with the peak incidence of MFS. Thirty-eight (52.8%) patients had a history of upper respiratory tract infection one week before onset, while 4 (5.6%) patients experienced gastrointestinal infections. Among the 65 patients who underwent lumbar puncture, 48 (73.8%) patients exhibited albumincytologic dissociation in the cerebrospinal fluid study. Overall, 83.5% patients presented with limited outward movement of the eye, 64.2% had bilateral symmetrical ophthalmoplegia, and only 25.4% had unilateral ophthalmoplegia. No significant differences were observed between the rural and urban areas, such as age of onset (p=0.777) or sex distribution (p=0.609). Patients with complete ophthalmoplegia were older than those with incomplete ophthalmoplegia ( 64.53±7.69 years vs 43.19±14.40 years, p<0.001). Conclusion: Winter and spring are the peaks of MFS incidence. The incidence is higher in men than in women. The most common pattern of ophthalmoplegia in MFS is bilateral symmetrical ophthalmoplegia, There is no urban-rural difference in MFS in southern China. Patients with complete ophthalmoplegia were older than incomplete ophthalmoplegia. There is no significant difference of MFS between southern China and other East Asian countries.
Guillain – Barré syndrome (GBS) is an immune-mediated neuropathy, the pathology of which is not clear. Both cellular and humoral immunity are involved in the occurrence of the disease, and molecular mimicry is currently the most widely recognized pathogenesis. Intravenous immunoglobulin (IVIg) and plasma exchange (PE) have been proven to be effective in improving the prognosis of patients with GBS, but there has been no progress in the treatment of the disease or strategies to improve the prognosis. New treatment strategies for GBS are mostly immunotherapies, including treatment against antibodies, complement pathways, immune cells and cytokines. Some of the new strategies are being investigated in clinical trials, but none of them have been approved for the treatment of GBS. Here, we summarized the current therapies for GBS, and new immunotherapies for GBS according to pathogenesis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.